ACCESSWIRE
26 Jan 2022, 22:50 GMT+10
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.
As part of an industry panel, Dr. Nijhawan is expected to discuss, among other topics, how Edesa adapted its drug development programs and aligned its business with government and industry priorities to respond to the COVID-19 health crisis.
The panel discussion, which is titled 'Pivoting and Adapting to the Changing Environment,' is scheduled to take place on Thursday, February 10, 2022 at 1:00 pm Eastern Time. More information is available at the event website.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts. Connect with us on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'will,' 'would,' 'could,' 'should,' 'might,' 'potential,' or 'continue' and variations or similar expressions, including statements related to scheduled events and the company's timing and plans regarding its drug development studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contacts
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
investors@edesabiotech.com
SOURCE: Edesa Biotech, Inc.
Get a daily dose of Albuquerque Express news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Albuquerque Express.
More InformationBEIJING, China: China's Foreign Ministry rebuked the U.S. for changing the wording about Taiwan on the State Department website, stressing ...
VATICAN CITY: While recovering from knee problems that have forced him to use a wheelchair last week, Pope Francis announced ...
SIALKOT, Pakistan - Pakistan Tehreek-e-Insaf (PTI) Chairman Imran Khan has claimed that a plot to kill him was being hatched, ...
BERLIN, Germany: Citing Interior Ministry data, Welt am Sonntag newspaper has reported that more than 700,000 people fleeing the war ...
WASHINGTON D.C.: The U.S. airline industry is pressuring the Biden administration to lift a 16-month-old regulation requiring a negative COVID-19 ...
DOLNI MORAVA, Czech Republic: The world's longest pedestrian suspension bridge has opened at a mountain resort in the Czech Republic. ...
NEW YORK, New York - Bargain-hunters drove up the prices of stocks on U.S. markets on Tuesday."Our inputs today support ...
NEW DELHI, India: India has banned the exporting of wheat, despite stating it was targeting record international shipments this year, ...
NEW DELHI, India: Tesla made known this week that it will not sell electric automobiles in India due to the ...
SYDNEY, NSW, Australia - A potential easing of the Chinese government's crackdown on technology companies drove stocks in Hong Kong ...
KATHMANDU, Nepal - The governments of Nepal and India have signed a bilateral memorandum of understanding for the construction of ...
LOS ANGELES, California: Kia has become the second largest manufacturer of electric vehicles sold in the United States, second only ...